No Manufacturer Listed

Rasagiline is a new medication which is used to treat Parkinson's disease either as monotherapy (by itself) or in addition to levodopa therapy. The main advantage of rasagiline over medications with similar mechanisms of action such as selegiline is that rasagiline breaks down and is eliminated in the body without producing any undesirable metabolites

Patients taking MAO (monoamine oxidase) inhibitors or pethidine should not take rasagiline (Azilect). There should be a minimum of 14 days from the stoppage of rasagiline and the beginning of treatment with MAO inhibitors or pethidine.

Rasagiline should not be administered at the same time as fluoxetine or fluvoxamine. Use of rasagiline with any other antidepressants should be approached with caution. Dextromethorphan or decongestants such as pseudoephedrine should also be avoided. Because of the manner rasagiline is removed from the body, there may also be interactions with medications such as ciprofloxacin, theophylline, entacapone, and other medications. Before starting rasagiline, patients should inform their prescriber of all medications that they take.